Inflammatory cyclooxygenase activity and PGE2 signaling in models of alzheimer’s disease

Current Immunology Reviews

Volumn 11, Issue 2, 2015, Pages 125-131

  Johansson, Jenny U ^a,b   Woodling, Nathaniel S ^a,c   Shi, Ju ^a,d   Andreasson, Katrin I ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SRI INTERNATIONAL   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d True North Therapeutics Inc   (United States)

Author keywords

Alzheimer s disease; Amyloid beta; Cyclooxgenases; EP2 receptor; EP3 receptor; EP4 receptor; Inflammation; Microglia; Prostaglandin E2

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CD33 ANTIGEN; G PROTEIN COUPLED RECEPTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; DISEASE COURSE; ENZYME ACTIVITY; EXCITOTOXICITY; GENE EXPRESSION; MICROGLIA; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNAPTOGENESIS;

EID: 84940943868     PISSN: 15733955     EISSN: 1875631X     Source Type: Journal    
DOI: 10.2174/1573395511666150707181414     Document Type: Article

References (100)

1. [1] Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60(8): 1119-22.
2. [2] Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21(3): 383-421.
3. [3] Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol 2007; 184(1-2): 69-91.
4. [4] Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367(9): 795-804.
5. [5] Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7(3): 280-92.
6. [6] Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011; 43(5): 436-41.
7. [7] Bertram L, Lange C, Mullin K, et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet 2008; 83(5): 623-32.
8. [8] Hollingworth P, Harold D, Sims R, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011; 43(5): 429-35.
9. [9] Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2013; 368(2): 117-27.
10. [10] Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 2013; 368(2): 107-16.
11. [11] Griciuc A, Serrano-Pozo A, Parrado AR, et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 2013; 78(4): 631-43.
12. [12] Malik M, Simpson JF, Parikh I, et al. CD33 Alzheimer's riskaltering polymorphism, CD33 expression, and exon 2 splicing. J Neurosci 2013; 33(33): 13320-5.
13. [13] Kleinberger G, Yamanishi Y, Suarez-Calvet M, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 2014; 6(243): 243ra86.
14. [14] Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013; 45(12): 1452-8.
15. [15] Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009; 41(10): 1094-9.
16. [16] Ginhoux F, Greter M, Leboeuf M, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010; 330(6005): 841-5.
17. [17] Ransohoff RM and Cardona AE. The myeloid cells of the central nervous system parenchyma. Nature 2010; 468(7321): 253-62.
18. [18] Butovsky O, Jedrychowski MP, Moore CS, et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci 2014; 17(1): 131-43.
19. [19] Hickman SE, Kingery ND, Ohsumi TK, et al. The microglial sensome revealed by direct RNA sequencing. Nat Neurosci 2013; 16(12): 1896-905.
20. [20] Gautier EL, Shay T, Miller J, et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol 2012; 13(11): 1118-28.
21. [21] Paolicelli RC, Bolasco G, Pagani F, et al. Synaptic pruning by microglia is necessary for normal brain development. Science 2011; 333(6048): 1456-8.
22. [22] Zhan Y, Paolicelli RC, Sforazzini F, et al. Deficient neuronmicroglia signaling results in impaired functional brain connectivity and social behavior. Nat Neurosci 2014; 17(3): 400-6.
23. [23] Schafer DP, Lehrman EK, Kautzman AG, et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 2012; 74(4): 691-705.
24. [24] Stevens B, Allen NJ, Vazquez LE, et al. The classical complement cascade mediates CNS synapse elimination. Cell 2007; 131(6): 1164-78.
25. [25] Kettenmann H, Kirchhoff F, Verkhratsky A. Microglia: new roles for the synaptic stripper. Neuron 2013; 77(1): 10-8.
26. [26] Szekely CA, Thorne JE, Zandi PP, et al. Nonsteroidal antiinflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 2004; 23(4): 159-69.
27. [27] Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997; 48: 626-32.
28. [28] Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345(21): 1515-21.
29. [29] McGeer PL, Schulzer M, and McGeer EG. Arthritis and antiinflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996; 47(2): 425-32.
30. [30] Vlad SC, Miller DR, Kowall NW, et al. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 2008; 70(19): 1672-7.
31. [31] Breitner JC, Baker LD, Montine TJ, et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement 2011; 7(4): 402-11.
32. [32] Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. Jama 2003; 289(21): 2819-26.
33. [33] Soininen H, West C, Robbins J, et al. Long-term efficacy and safety of celecoxib in Alzheimer's disease. Dement Geriatr Cogn Disord 2007; 23(1): 8-21.
34. [34] Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005; 30(6): 1204-15.
35. [35] Lyketsos CG, Breitner JC, Green RC, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007; 68(21): 1800-8.
36. [36] Martin BK, Szekely C, Brandt J, et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 2008; 65(7): 896-905.
37. [37] Andreasson K. Emerging roles of PGE2 receptors in models of neurological disease. Prostaglandins Other Lipid Mediat 2010; 91(3-4): 104-12.
38. [38] Egan KM, Lawson JA, Fries S, et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004; 306(5703): 1954-7.
39. [39] Funk CD, FitzGerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 2007; 50(5): 470-9.
40. [40] Liang X, Lin L, Wang Q, et al. Neuronal and vascular protection by the prostaglandin E2 EP4 receptor in a mouse model of cerebral ischemia. J Clin Invest 2011; 121(11): 4362-71.
41. [41] Shi J, Johansson J, Woodling NS, et al. The prostaglandin E2 Eprostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J Immunol 2010; 184(12): 7207-18.
42. [42] Woodling NS, Wang Q, Priyam PG, et al. Suppression of Alzheimer-Associated Inflammation by Microglial Prostaglandin-E2 EP4 Receptor Signaling. J Neurosci 2014; 34(17): 5882-94.
43. [43] Leoutsakos JM, Muthen BO, Breitner JC, et al. Effects of nonsteroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial. Int J Geriatr Psychiatry 2011.
44. [44] Breyer RM, Bagdassarian CK, Myers SA, et al. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001; 41: 661-90.
45. [45] Montine TJ, Sidell KR, Crews BC, et al. Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 1999; 53(7): 1495-8.
46. [46] Combrinck M, Williams J, De Berardinis MA, et al. Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2006; 77(1): 85-8.
47. [47] Johansson JU, Pradhan, S, Lokteva LA, et al. Suppression of inflammation with conditional deletion of the prostaglandin E2 EP2 receptor in macrophages and brain microglia. J Neurosci 2013; 33: 16012-32.
48. [48] Slawik H, Volk B, Fiebich B, et al. Microglial expression of prostaglandin EP3 receptor in excitotoxic lesions in the rat striatum. Neurochem Int 2004; 45(5): 653-60.
49. [49] Mucke L, Selkoe DJ. Neurotoxicity of Amyloid beta-Protein: Synaptic and Network Dysfunction. Cold Spring Harb Perspect Med 2012; 2(7): a006338.
50. [50] Hein AM, Stasko MR, Matousek SB, et al. Sustained hippocampal IL-1beta overexpression impairs contextual and spatial memory in transgenic mice. Brain Behav Immun 2010; 24(2): 243-53.
51. [51] Medeiros R, Prediger RD, Passos GF, et al. Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J Neurosci 2007; 27(20): 5394-404.
52. [52] Ashe KH, Zahs KR. Probing the biology of Alzheimer's disease in mice. Neuron 2010; 66(5): 631-45.
53. [53] Yan Q, Zhang J, Liu H, et al. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 2003; 23(20): 7504-9.
54. [54] Lim GP, Yang F, Chu T, et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging 2001; 22(6): 983-91.
55. [55] Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 2000; 20(15): 5709-14.
56. [56] Kotilinek LA, Westerman MA, Wang Q, et al. Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain 2008; 131(Pt 3): 651-64.
57. [57] Montine TJ, Milatovic D, Gupta RC, et al. Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent. J Neurochem 2002; 83(2): 463-70.
58. [58] Shie FS, Montine KS, Breyer RM, et al. Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity. Glia 2005; 52(1): 70-7.
59. [59] Liang X, Wang Q, Lokteva L, et al. The PGE2 PE2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Soc. Neuroscience 2007; 2007(160.16).
60. [60] Liang X, Wang Q, Shi J, et al. The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann Neurol 2008; 64(3): 304-14.
61. [61] Lee CY, Landreth GE. The role of microglia in amyloid clearance from the AD brain. J Neural Transm 2010; 117(8): 949-60.
62. [62] Hickman SE, Allison EK, and El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci 2008; 28(33): 8354-60.
63. [63] Landreth GE, Reed-Geaghan EG. Toll-like receptors in Alzheimer's disease. Curr Top Microbiol Immunol 2009; 336: 137-53.
64. [64] Shie FS, Breyer RM, Montine TJ. Microglia lacking E Prostanoid Receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity. Am J Pathol 2005; 166(4): 1163-72.
65. [65] Liang X, Wang Q, Hand T, et al. Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J Neurosci 2005; 25(44): 10180-7.
66. [66] Keene CD, Chang RC, Lopez-Yglesias AH, et al. Suppressed accumulation of cerebral amyloid {beta} peptides in aged transgenic Alzheimer's disease mice by transplantation with wildtype or prostaglandin E2 receptor subtype 2-null bone marrow. Am J Pathol 2010; 177(1): 346-54.
67. [67] Chuang PC, Lin YJ, Wu MH, et al. Inhibition of CD36-dependent phagocytosis by prostaglandin E2 contributes to the development of endometriosis. Am J Pathol 2010; 176(2): 850-60.
68. [68] Nagano T, Kimura SH, and Takemura M. Prostaglandin E2 reduces amyloid beta-induced phagocytosis in cultured rat microglia. Brain Res 2010; 1323: 11-7.
69. [69] Aronoff DM, Hao Y, Chung J, et al. Misoprostol impairs female reproductive tract innate immunity against Clostridium sordellii. J Immunol 2008; 180(12): 8222-30.
70. [70] Ballinger MN, Aronoff DM, McMillan TR, et al. Critical role of prostaglandin E2 overproduction in impaired pulmonary host response following bone marrow transplantation. J Immunol 2006; 177(8): 5499-508.
71. [71] Medeiros AI, Serezani CH, Lee SP, et al. Efferocytosis impairs pulmonary macrophage and lung antibacterial function via PGE2/EP2 signaling. J Exp Med 2009; 206(1): 61-8.
72. [72] Aronoff DM, Canetti C, and Peters-Golden M. Prostaglandin E2 in hibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. J Immunol 2004; 173(1): 559-65.
73. [73] Johansson JU, Woodling NS, Wang Q, et al. Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models. J Clin Invest 2015; 125(1): 350-64.
74. [74] Fernandez AM and Torres-Aleman I. The many faces of insulinlike peptide signalling in the brain. Nat Rev Neurosci 2012; 13(4): 225-39.
75. [75] Heneka MT, Landreth GE, Hull M. Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders. Nat Clin Pract Neurol 2007; 3(9): 496-504.
76. [76] Yamanaka M, Ishikawa T, Griep A, et al. PPARgamma/RXRalphainduced and CD36-mediated microglial amyloid-beta phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J Neurosci 2012; 32(48): 17321-31.
77. Cramer PE, Cirrito JR, Wesson DW, et al. ApoE-directed therapeutics rapidly clear
78. [78] Fitz NF, Cronican AA, Lefterov I, et al. Comment on "ApoEdirected therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 2013; 340(6135): 924-c.
79. [79] Chawla A, Boisvert WA, Lee CH, et al. A PPAR gamma-LXRABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001; 7(1): 161-71.
80. [80] Laffitte BA, Repa JJ, Joseph SB, et al. LXRs control lipidinducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci U S A 2001; 98(2): 507-12.
81. [81] Jiang Q, Lee CY, Mandrekar S, et al. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008; 58(5): 681-93.
82. [82] Mandrekar-Colucci S, Karlo JC, and Landreth GE. Mechanisms underlying the rapid peroxisome proliferator-activated receptorgamma- mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J Neurosci 2012; 32(30): 10117-28.
83. [83] Nishitsuji K, Hosono T, Uchimura K, et al. Lipoprotein lipase is a novel amyloid beta (Abeta)-binding protein that promotes glycosaminoglycan-dependent cellular uptake of Abeta in astrocytes. J Biol Chem 2011; 286(8): 6393-401.
84. [84] Blain JF, Aumont N, Theroux L, et al. A polymorphism in lipoprotein lipase affects the severity of Alzheimer's disease pathophysiology. Eur J Neurosci 2006; 24(5): 1245-51.
85. [85] Takayama K, Sukhova GK, Chin MT, et al. A novel prostaglandin E receptor 4-associated protein participates in antiinflammatory signaling. Circ Res 2006; 98(4): 499-504.
86. [86] Minami M, Shimizu K, Okamoto Y, et al. Prostaglandin E receptor type 4-associated protein interacts directly with NF-kappaB1 and attenuates macrophage activation. J Biol Chem 2008; 283(15): 9692-703.
87. [87] Lazarus M, Yoshida K, Coppari R, et al. EP3 prostaglandin receptors in the median preoptic nucleus are critical for fever responses. Nat Neurosci 2007; 10(9): 1131-3.
88. [88] Ushikubi F, Segi E, Sugimoto Y, et al. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature 1998; 395(6699): 281-4.
89. [89] Aronoff DM, Lewis C, Serezani CH, et al. E-prostanoid 3 receptor deletion improves pulmonary host defense and protects mice from death in severe Streptococcus pneumoniae infection. J Immunol 2009; 183(4): 2642-9.
90. [90] Letiembre M, Liu Y, Walter S, et al. Screening of innate immune receptors in neurodegenerative diseases: A similar pattern. Neurobiol Aging 2007.
91. [91] Walter S, Letiembre M, Liu Y, et al. Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cell Physiol Biochem 2007; 20(6): 947-56.
92. [92] Shi J, Wang Q, Johansson JU, et al. Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease. Ann Neurol 2012; 72(5): 788-98.
93. [93] Tamagno E, Bardini P, Obbili A, et al. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 2002; 10(3): 279-88.
94. [94] Apelt J, Bigl M, Wunderlich P, et al. Aging-related increase in oxidative stress correlates with developmental pattern of betasecretase activity and beta-amyloid plaque formation in transgenic Tg2576 mice with Alzheimer-like pathology. Int J Dev Neurosci 2004; 22(7): 475-84.
95. [95] Candelario-Jalil E, Slawik H, Ridelis I, et al. Regional distribution of the prostaglandin E2 receptor EP1 in the rat brain: accumulation in Purkinje cells of the cerebellum. J Mol Neurosci 2005; 27(3): 303-10.
96. [96] Kawano T, Anrather J, Zhou P, et al. Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med 2006; 12(2): 225-9.
97. [97] Ahmad AS, Saleem S, Ahmad M, et al. Prostaglandin EP1 receptor contributes to excitotoxicity and focal ischemic brain damage. Toxicol Sci 2006; 89(1): 265-70.
98. [98] Zhen G, Kim YT, Li RC, et al. PGE2 EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral ischemia and Alzheimer's disease. Neurobiol Aging 2012; 33(9): 2215-9.
99. [99] Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003; 302(5651): 1760-5.
100. [100] Keene CD, Chang R, Stephen C, et al. Protection of hippocampal neurogenesis from toll-like receptor 4-dependent innate immune activation by ablation of prostaglandin E2 receptor subtype EP1 or EP2. Am J Pathol 2009; 174(6): 2300-9.